Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia
Arnon Nagler(Sheba Medical Center), Mohamad Mohty(Sorbonne Université), Boris V. Afanasyev(First Pavlov State Medical University of St. Petersburg), Fabio Ciceri(Vita-Salute San Raffaele University), Johanna Tischer(LMU Klinikum), Myriam Labopin(Sorbonne Université), Sebastian Giebel(The Maria Sklodowska-Curie National Research Institute of Oncology), William Arcese(University of Rome Tor Vergata), Zafer Gülbaş, Zinaida Perić(University of Rijeka), Abraham S. Kanate(HonorHealth), Emanuele Angelucci(Ospedale Policlinico San Martino), Yener Koç(Antalya IVF), Bipin N. Savani(Vanderbilt University Medical Center), Pietro Pioltelli(University of Milan), Mutlu Arat(Istanbul Florence Nightingale Hospital), Depei Wu(Soochow University), Hakan Özdoğu(Başkent University)
Cited by 56
Related Papers
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2016|538
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
|Nature Medicine|2023|534